DK1124804T3 - Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase - Google Patents
Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntaseInfo
- Publication number
- DK1124804T3 DK1124804T3 DK99953259T DK99953259T DK1124804T3 DK 1124804 T3 DK1124804 T3 DK 1124804T3 DK 99953259 T DK99953259 T DK 99953259T DK 99953259 T DK99953259 T DK 99953259T DK 1124804 T3 DK1124804 T3 DK 1124804T3
- Authority
- DK
- Denmark
- Prior art keywords
- cox
- inhibitors
- cyclooxygenase
- biosynthesis
- synthase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17960598A | 1998-10-27 | 1998-10-27 | |
| US26187299A | 1999-03-03 | 1999-03-03 | |
| US29849099A | 1999-04-23 | 1999-04-23 | |
| US09/427,768 US6307047B1 (en) | 1997-08-22 | 1999-10-27 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1124804T3 true DK1124804T3 (da) | 2005-12-12 |
Family
ID=27497355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99953259T DK1124804T3 (da) | 1998-10-27 | 1999-10-27 | Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1124804B1 (da) |
| JP (1) | JP2003512292A (da) |
| KR (1) | KR100666838B1 (da) |
| CN (1) | CN1279026C (da) |
| AT (1) | ATE302759T1 (da) |
| BG (1) | BG65261B1 (da) |
| BR (1) | BR9914858A (da) |
| CA (1) | CA2347982A1 (da) |
| CZ (1) | CZ300570B6 (da) |
| DE (1) | DE69926903T2 (da) |
| DK (1) | DK1124804T3 (da) |
| ES (1) | ES2249919T3 (da) |
| HK (1) | HK1041876B (da) |
| HU (1) | HUP0105248A3 (da) |
| NO (1) | NO318623B1 (da) |
| PL (1) | PL198503B1 (da) |
| SK (1) | SK286806B6 (da) |
| TR (1) | TR200101765T2 (da) |
| WO (1) | WO2000024719A1 (da) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1043317B1 (en) | 1997-11-19 | 2009-04-15 | Kowa Co., Ltd. | Pyridazine derivatives and medicaments containing them as active ingredient |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| JP2000247959A (ja) | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−３−オン誘導体及びこれを含有する医薬 |
| SK12672001A3 (sk) | 1999-12-08 | 2002-04-04 | Pharmacia Corporation | Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku |
| US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
| US6716829B2 (en) | 2000-07-27 | 2004-04-06 | Pharmacia Corporation | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders |
| AR030741A1 (es) | 2000-09-15 | 2003-09-03 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa |
| AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
| US7012098B2 (en) | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
| DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| NZ534395A (en) | 2002-02-14 | 2006-10-27 | Pharmacia Corp | Substituted pyridinones as modulators of p38 MAP kinase |
| SI1572173T1 (sl) | 2002-12-13 | 2010-08-31 | Warner Lambert Co | Alfa-2-delta ligand za zdravljenje simptomov spodnjega dela sečil |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| EP1604984A1 (en) | 2003-03-18 | 2005-12-14 | Kowa Co., Ltd. | Water-soluble phenylpyridazine derivative and medicine containing the same |
| EP1745791B1 (en) | 2003-05-07 | 2013-06-26 | Osteologix A/S | Treating cartilage/bone conditions with water-soluble strontium salts |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| EP1916240A1 (en) * | 2006-10-25 | 2008-04-30 | Syngeta Participations AG | Pyridazine derivatives |
| EA017171B1 (ru) | 2006-12-22 | 2012-10-30 | Рекордати Айерленд Лимитед | КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП) |
| DE102007008839A1 (de) * | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen |
| DE102007008840A1 (de) | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP) |
| DE102007008843A1 (de) | 2007-02-23 | 2008-08-28 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen |
| DE102007020690A1 (de) | 2007-05-03 | 2008-11-06 | Bayer Healthcare Ag | Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP) |
| DE102007020689A1 (de) | 2007-05-03 | 2008-11-06 | Bayer Healthcare Ag | Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP) |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| GB0716414D0 (en) * | 2007-08-22 | 2007-10-03 | Syngenta Participations Ag | Novel insecticides |
| EP2188288A1 (en) | 2007-09-11 | 2010-05-26 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
| GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| JP2012131708A (ja) * | 2009-04-28 | 2012-07-12 | Nissan Chem Ind Ltd | ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤 |
| FR2969606B1 (fr) * | 2010-12-22 | 2013-01-11 | Pf Medicament | Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US11583516B2 (en) | 2016-09-07 | 2023-02-21 | Trustees Of Tufts College | Dash inhibitors, and uses related thereto |
| CN107334767B (zh) * | 2017-06-08 | 2019-03-05 | 中国医学科学院医药生物技术研究所 | 一种哒嗪酮类化合物在肿瘤治疗中的应用 |
| WO2021124344A1 (en) * | 2019-12-18 | 2021-06-24 | Abida | Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4238490A (en) * | 1979-02-12 | 1980-12-09 | Diamond Shamrock Corporation | Antihypertensive pyridazin(2H)-3-ones |
| JPS57501328A (da) * | 1980-08-07 | 1982-07-29 | ||
| US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| CA2224563A1 (en) * | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations |
| JP2001514669A (ja) * | 1997-03-14 | 2001-09-11 | メルク フロスト カナダ アンド カンパニー | シクロオキシゲナーゼ−２阻害薬としてのピリダジノン類 |
| DE69833774T2 (de) * | 1997-08-22 | 2007-04-26 | Abbott Laboratories, Abbott Park | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren |
| CA2299300C (en) * | 1997-08-22 | 2007-04-17 | Abbott Laboratories | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors |
| IL133552A (en) * | 1997-08-22 | 2005-12-18 | Abbott Lab | Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors |
-
1999
- 1999-10-27 PL PL349256A patent/PL198503B1/pl not_active IP Right Cessation
- 1999-10-27 WO PCT/US1999/025234 patent/WO2000024719A1/en active Application Filing
- 1999-10-27 CA CA002347982A patent/CA2347982A1/en not_active Abandoned
- 1999-10-27 CZ CZ20011481A patent/CZ300570B6/cs not_active IP Right Cessation
- 1999-10-27 ES ES99953259T patent/ES2249919T3/es not_active Expired - Lifetime
- 1999-10-27 TR TR2001/01765T patent/TR200101765T2/xx unknown
- 1999-10-27 SK SK554-2001A patent/SK286806B6/sk not_active IP Right Cessation
- 1999-10-27 EP EP99953259A patent/EP1124804B1/en not_active Expired - Lifetime
- 1999-10-27 BR BR9914858-7A patent/BR9914858A/pt not_active IP Right Cessation
- 1999-10-27 CN CNB998147265A patent/CN1279026C/zh not_active Expired - Fee Related
- 1999-10-27 DK DK99953259T patent/DK1124804T3/da active
- 1999-10-27 JP JP2000578289A patent/JP2003512292A/ja not_active Ceased
- 1999-10-27 KR KR1020017005342A patent/KR100666838B1/ko not_active IP Right Cessation
- 1999-10-27 AT AT99953259T patent/ATE302759T1/de not_active IP Right Cessation
- 1999-10-27 DE DE69926903T patent/DE69926903T2/de not_active Expired - Lifetime
- 1999-10-27 HU HU0105248A patent/HUP0105248A3/hu unknown
-
2001
- 2001-04-26 NO NO20012061A patent/NO318623B1/no not_active IP Right Cessation
- 2001-05-19 BG BG105523A patent/BG65261B1/bg unknown
-
2002
- 2002-02-19 HK HK02101207.5A patent/HK1041876B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1041876B (zh) | 2006-06-23 |
| CA2347982A1 (en) | 2000-05-04 |
| NO318623B1 (no) | 2005-04-18 |
| JP2003512292A (ja) | 2003-04-02 |
| TR200101765T2 (tr) | 2002-02-21 |
| SK5542001A3 (en) | 2001-12-03 |
| EP1124804B1 (en) | 2005-08-24 |
| HUP0105248A2 (hu) | 2002-07-29 |
| NO20012061D0 (no) | 2001-04-26 |
| PL198503B1 (pl) | 2008-06-30 |
| KR100666838B1 (ko) | 2007-01-11 |
| CN1342149A (zh) | 2002-03-27 |
| ES2249919T3 (es) | 2006-04-01 |
| BG105523A (en) | 2001-12-29 |
| EP1124804A1 (en) | 2001-08-22 |
| DE69926903T2 (de) | 2006-07-13 |
| CZ20011481A3 (cs) | 2001-09-12 |
| ATE302759T1 (de) | 2005-09-15 |
| BG65261B1 (bg) | 2007-10-31 |
| BR9914858A (pt) | 2002-02-05 |
| CN1279026C (zh) | 2006-10-11 |
| HK1041876A1 (en) | 2002-07-26 |
| WO2000024719A1 (en) | 2000-05-04 |
| DE69926903D1 (en) | 2005-09-29 |
| CZ300570B6 (cs) | 2009-06-17 |
| SK286806B6 (sk) | 2009-05-07 |
| KR20010081101A (ko) | 2001-08-27 |
| PL349256A1 (en) | 2002-07-01 |
| HUP0105248A3 (en) | 2002-09-30 |
| NO20012061L (no) | 2001-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1124804T3 (da) | Inhibitorer for biosyntesen af prostaglandin-endoperoxid-H-syntase | |
| DK1005460T3 (da) | Inhibitorer af biosyntesen af prostaglandin-endoperoxid H-synthase | |
| CA2299300A1 (en) | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors | |
| Reddy et al. | C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages | |
| Frölich | A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes | |
| Pairet et al. | Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs | |
| Chan et al. | Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles | |
| Zschocke et al. | Cryptocarya species—substitute plants for Ocotea bullata? A pharmacological investigation in terms of cyclooxygenase-1 and-2 inhibition | |
| Chen et al. | Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins | |
| BRPI0011172B8 (pt) | derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2 | |
| EP1391201A4 (en) | MEDICAL COMPOSITIONS | |
| Thérien et al. | Synthesis and biological evaluation of 5, 6-diarylimidazo [2.1-b] thiazole as selective COX-2 inhibitors | |
| Ramalho et al. | The search for new COX-2 inhibitors: a review of 2002–2008 patents | |
| Bhat et al. | Novel sulindac derivatives: Synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity | |
| Aprioku et al. | Renal effects of non-steroidal anti inflammatory drugs in albino rats | |
| FR2897864B1 (fr) | Composition d'amorcage et applications | |
| Varandas et al. | Design, synthesis and pharmacological evaluation of new nonsteroidal antiinflammatory 1, 3, 4-thiadiazole derivatives | |
| Bastaki et al. | Effect of aspirin and ibuprofen either alone or in combination on gastric mucosa and bleeding time and on serum prostaglandin E 2 and thromboxane A 2 levels in the anaesthetized rats in vivo | |
| Biava | Introduction to COX inhibitors | |
| TR200000478T2 (tr) | Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar. | |
| Lau et al. | From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors | |
| Berg et al. | Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells | |
| Murphy et al. | Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines | |
| De Godoy et al. | Arachidonic acid metabolites follow the preferential course of cyclooxygenase pathway for the basal tone in the internal anal sphincter | |
| Ayoub et al. | Inhibition of the diclofenac‐induced cyclooxygenase‐2 activity by paracetamol in cultured macrophages is not related to the intracellular lipid hydroperoxide tone |